A Phase II Study of the Interleukin-6 Receptor Inhibitor Sarilumab in Combination with Ipilimumab Nivolumab and Relatlimab in Patients with Unresectable Stage III or Stage IV Melanoma
Brief description of study
A Phase II Study of the Interleukin-6 Receptor Inhibitor Sarilumab in Combination with Ipilimumab, Nivolumab and Relatlimab in Patients with Unresectable Stage III or Stage IV Melanoma
Clinical Study Identifier: s22-00325
ClinicalTrials.gov Identifier: NCT05428007
Principal Investigator:
Janice Mehnert.
Other Investigators:
Nila Theresa De La Rosa,
Maya Dimitrova,
Rafael Winograd,
Kathleen M Madden,
Kristen Spencer.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.